SMA patients’ parents in Kerala worried about move to buy generic drug for govt. scheme
Parents of children with Spinal Muscular Atrophy in Kerala are protesting the government's plan to switch to a generic version of the drug risdiplam. They argue that the generic version lacks necessary clinical trials and safety data compared to the innovator drug.
Why it matters
It raises critical questions about healthcare policy, the safety of generic drug substitution for rare diseases, and patient advocacy.
Parents of children with Spinal Muscular Atrophy (SMA) in Kerala are worried about the State government’s move to buy a generic version of a life-saving medicine to be distributed among them for free, as it has not undergone clinical trials so far.
The article focuses heavily on the concerns of the parents and patient advocates, highlighting potential risks to vulnerable populations.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in